35582-78-6

Basic information

• Product Name: (±)-4-(3,4-dimethoxyphenyl)-7-hydroxy-3,4-dihydrocoumarin
• Synonyms: (±)-4-(3,4-dimethoxyphenyl)-7-hydroxy-3,4-dihydrocoumarin
• CAS NO: 35582-78-6
• Molecular Weight: 300.311
• Mol File: 35582-78-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (±)-4-(3,4-dimethoxyphenyl)-7-hydroxy-3,4-dihydrocoumarin(CAS DataBase Reference)
• NIST Chemistry Reference: (±)-4-(3,4-dimethoxyphenyl)-7-hydroxy-3,4-dihydrocoumarin(35582-78-6)
• EPA Substance Registry System: (±)-4-(3,4-dimethoxyphenyl)-7-hydroxy-3,4-dihydrocoumarin(35582-78-6)

Safety Data

• Hazardous Substances Data: 35582-78-6(Hazardous Substances Data)

Upstream product

• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 22511-06-4 3,4-dimethoxyphenylpropiolic acid 
• 108-46-3 recorcinol 
• 2316-26-9 3,4-dimethoxycinnamic acid 

Relevant articles and documents

Synthesis and biological evaluation of novel neoflavonoid derivatives as potential antidiabetic agents

Various substituted neoflavonoid derivatives were synthesized using sulfated montmorillonite K-10 as a catalyst. This method is environmental friendly, sustainable and economical, convenient in isolation and purification processes, with little byproducts, using earth-abundant catalysts and has relatively high yield. Those neoflavonoid derivatives were screened for antioxidant, a-glucosidase inhibitory, aldose reductase 2 (ALR2) inhibitory and advanced glycation end-product formation inhibitory effects. Most compounds exhibited significant antioxidant and advanced glycation end-product (AGE) formation inhibitory activities. It was interesting to note that out of thirty compounds, 8k and 8l were found to have greater ALR2 inhibitory activity than the standard drug quercetin. The pharmacological studies suggested neoflavonoid with adjacent 7,8-dihydroxy groups were more effective in inhibiting ALR2. Antidiabetic activity studies had shown that compounds 8l and 8m were equipotent to the standard drug glibenclamide in vivo. In summary, the target compound 8l provided a potential drug design concept for the development of therapeutic or prophylactic agents of diabetes and diabetes complications.

Preparation method of 3,4-dihydro-4-arylcoumarin compounds

The invention relates to the field of chemical synthesis, and concretely relates to a preparation method of 3,4-dihydro-4-arylcoumarin compounds. The method is characterized in that: substituted benzaldehyde is used as an initial raw material, propane diacid is added, a reaction is carried out with catalysis of piperidine, and substituted phenyl acrylic acid derivatives are obtained; montmorillonite K-10 which is acidified by sulfuric acid is used as a catalyst, a reaction between the substituted phenyl acrylic acid derivatives and phenolic compounds is carried out with heating, and the 3,4-dihydro-4-arylcoumarin compounds are obtained. Compared with the prior art, the preparation method of the 3,4-dihydro-4-arylcoumarin compounds has the advantages of easily available and cheap raw materials, simple operation, recyclable catalyst, environmental protection, simple post-treatment, low production cost, good promotion application, etc.

Synthesis and NMR of 4-Aryl-3,4-dihydrocoumarins and 4-arylcoumarins

This paper described the synthesis and 1H and 13C NMR chemical shifts of a series of 4-aryl-3,4-dihydrocoumarin and 4-arylcoumarin derivatives based on a combination of 1H and 13C NMR, HSQC and HMBC experiments.